Hemoglobin (Hb) levels in patients initiating dialysis have been declining since 2007, a trend that corresponds to decreased use of erythropoiesis-stimulating agents (ESAs) in pre-dialysis patients, according to investigators who presented a study at Renal Week 2010 in Denver.
Renal transplant recipients who receive epoetin (EPO) treatment for post-transplant anemia may experience slower declines in kidney function, according to a study presented at Renal Week 2010 in Denver.
